Genmab — Januar 2026

[E_L]

Just for interest, JNJ tried another PSMAxCD3 bispecific antibody, after discontinuing the PSMAxCD3 DuoBody a few years ago (JNJ-63898081). Spoiler: it also failed
https://link.springer.com/article/10.1007/s00280-025-04846-w

[Sukkeralf]

JNJ have taken a another TCE in phase 3 - a KLK2/CD3 made with Zymeworks
platform and has talked about a 1-5 billion peaksale.

[E_L]

jeez and they are going fast there i see, first-in-human results only last summer , directly to Ph3, skipping Ph2...

[tdmtintin]

Inside Genmab’s plan to use Anthropic’s AI to speed drug research

Genmab teams will use custom Claude-powered AI agents for data analysis and document generation under human oversight across clinical development.

Stock Titan (www.stocktitan.net)

[E_L]

when we approached the 2150 area around Christmas i thought, this could seriously pop upon breaking this area... but then the Acasunlimab drop seemed to throw ice on the fire... did not expect this quick return here...

[E_L]

the october high was 2153

[E_L]

where is @Legolas23 ? he normally spots these cup /handles...

[Raun]

Det har været tydeligt de seneste par dage at US har handl
et aktien op og DK handlet aktien ned

[Legolas23]

I'm here. But do you think it's a cwh we there? I think it's strong if the resistance in 2134 is broken?

[E_L]

i guess there is a small ugly one starting 1 Dec with cup 2111 - 2138 , but there is a bigger one 17 oct cup 2153 - 2138 ?

[E_L]

with the bottom of the cup at 1807 you could project a target of 2484 from the 2138 handle break-out

[E_L]

the EPCORE CLL-1 completion dates moved forward by 1 1/2 year, maybe due to fast recruitment? https://clinicaltrials.gov/study/NCT04623541?tab=history&a=34&b=35&compareMode=sideBySide#version-content-panel really curious if CLL will be pursued with Epco...

[E_L]

RAINFOL-04 starts recruiting https://clinicaltrials.gov/study/NCT07225270?tab=history&a=5&b=6#version-content-panel

[Legolas23]

I agree with you. The CWH is full filled. Target 2600.

[ProinvestorNEWS]

Genmab accelerer arbejdet med AI - indgår partnerskab med Anthropic https://proinvestor.com/investornyt/1400587/genmab-accelerer-arbejdet-med-ai-indgar-partnerskab-med-anthropic

[w]

UBS has raised its price target for Genmab to 2,750 Danish kroner (previously 2,700), and reiterates its buy recommendation.

[bongobob]

Den AI meddelelse er lidt en tynd kop te. R&D har noget at bevise og jeg forventer mig mere af deres interne data mining end AI https://claude.com/solutions/life-sciences

[E_L]

more on UBS - believes Genmab has the potential to transform its equity story in 2026, naming it as the firm’s top pick for European biotech in 2026 https://www.investing.com/news/analyst-ratings/ubs-raises-genmab-stock-price-target-to-dkk2750-on-pipeline-potential-93CH-4436366

[StockBull]

Her opdateret kanal. Trenden er stadig op. Solgte 50% af mine Genmab igår i kurs 2200 området. Forventer at kunne købe under 2100 senere. Ser +2500 omkring April / Maj - 2026

Tryk på billed for af gøre større https://proinvestor.com/boards/125146/$/130622

[StockBull]

Trenden stadig op men forventer en mindre retracement på dagkortet og så vidre op mod +2500 i H1